Market open
Vor Biopharma/$VOR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Vor Biopharma
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
Ticker
$VOR
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
159
Website
Vor Biopharma Metrics
BasicAdvanced
$81M
-
-$1.70
-0.41
-
Price and volume
Market cap
$81M
Beta
-0.41
52-week high
$1.95
52-week low
$0.49
Average daily volume
248K
Financial strength
Current ratio
5.185
Quick ratio
4.939
Long term debt to equity
28.568
Total debt to equity
32.928
Management effectiveness
Return on assets (TTM)
-44.42%
Return on equity (TTM)
-94.52%
Valuation
Price to book
0.84
Price to tangible book (TTM)
0.84
Price to free cash flow (TTM)
-0.447
Growth
Earnings per share change (TTM)
-2.99%
3-year earnings per share growth (CAGR)
-6.73%
What the Analysts think about Vor Biopharma
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Vor Biopharma stock.
Vor Biopharma Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Vor Biopharma Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Vor Biopharma News
AllArticlesVideos
Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
GlobeNewsWire·4 weeks ago
Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials
GlobeNewsWire·2 months ago
Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Vor Biopharma stock?
Vor Biopharma (VOR) has a market cap of $81M as of April 17, 2025.
What is the P/E ratio for Vor Biopharma stock?
The price to earnings (P/E) ratio for Vor Biopharma (VOR) stock is 0 as of April 17, 2025.
Does Vor Biopharma stock pay dividends?
No, Vor Biopharma (VOR) stock does not pay dividends to its shareholders as of April 17, 2025.
When is the next Vor Biopharma dividend payment date?
Vor Biopharma (VOR) stock does not pay dividends to its shareholders.
What is the beta indicator for Vor Biopharma?
Vor Biopharma (VOR) has a beta rating of -0.41. This means that it has an inverse relation to market volatility.